ALXO
ALX Oncology Holdings Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
ALX Oncology Holdings Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
ALX Oncology Holdings Inc
1.24
+0.02 · +1.38%
post 1.24 0.00%
ALX Oncology has 15 disclosed suppliers and 0 disclosed customers in SEC filings.
Sentenceo Our collaborator, Jazz Pharmaceuticals plc (Jazz), sponsored and managed the Phase 1b/2 trial of zanidatamab, a HER2-targeted anti-cancer antibody, for the treatment of advanced HER2-expressing breast cancer and other solid tumors in combination with evorpacept (Zanidatamab Trial).
Sentenceo In April 2023, we announced a collaboration with Sanofi who will sponsor and manage a Phase 1/2 trial of SARCLISA ® (isatuximab-irfc), an anti-cancer antibody, and dexamethasone in combination with evorpacept for the treatment of patients with relapsed or refractory multiple myeloma.
SentenceWe obtained a worldwide, royalty-bearing, sublicensable license from the Board of Trustees of the Leland Stanford Junior University, or Stanford, under certain patents relating to high-affinity SIRPα variant polypeptides, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe first entered into an engagement with KBI Biopharma, Inc. in 2015 for evorpacept analytical method development, formulation development, bulk drug manufacturing, release and stability testing.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe first entered into a drug product manufacturing agreement with Lyophilization Services of New England, Inc. (now PCI Pharma Services) in 2016 for evorpacept drug product used in clinical trials.
ALXO 10-Kaccession 0001193125-26-098454
Sentenceo In 2021, an IST of evorpacept was initiated in combination with rituximab and lenalidomide (R 2 ) for the treatment of patients with indolent and aggressive NHL, sponsored by MD Anderson Cancer Center in Texas.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe first entered into an engagement with Patheon Biologics LLC in 2022 for evorpacept bulk drug manufacturing and release testing.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe subsequently entered into a drug product manufacturing agreement with Patheon UK Limited in 2022 for drug product production of evorpacept drug product used in clinical trials.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWhile we have cash in operating accounts with SVB, the majority of our cash, cash equivalents and investments are deposited in custodial accounts held by U.S. Bank for which SVB Asset Management is the investment advisor.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe maintain the confidentiality of trade secrets and proprietary information in part by entering into confidentiality agreements with our employees, consultants, other service providers, including former service provider Tallac Therapeutics, strategic partners and others upon the commencement of their relationships with us.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe first entered into an engagement with WuXi Biologics and WuXi XDC in 2023 for ALX2004 analytical method development, formulation development, bulk drug manufacturing, drug product manufacturing, release and stability testing, used in clinical trials.
ALXO 10-Kaccession 0001193125-26-098454
SentenceWe first entered into an engagement with WuXi Biologics and WuXi XDC in 2023 for ALX2004 analytical method development, formulation development, bulk drug manufacturing, drug product manufacturing, release and stability testing, used in clinical trials.
ALXO 10-Kaccession 0001193125-26-098454
Sentenceo Our initial collaborator for the Zanidatamab Trial was Zymeworks Inc. (Zymeworks), however in a series of transactions commencing in October 2022, Jazz assumed responsibility from Zymeworks for the development and commercialization of zanidatamab in the United States, Europe, Japan and certain other territories, including responsibility for the Zanidatamab Trial.
ALXO 10-Kaccession 0001193125-26-098454
—
—
Linked news
Expected move
No implied move.